AMEERA-3: Randomized Phase II Study of Amcenestrant (Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Monotherapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer.

J Clin Oncol · 2023 · PMC10461947 · PMID 37348019

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

27 In AMEERA-3, among patients with baseline mESR1 (46.4%), amcenestrant showed a trend of longer PFS compared with TPC (3.7 v 2.0 months; stratified HR, 0.9 [95% CI, 0.565 to 1.435]).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.